ATRA Rises On Pushing For Meeting With FDA On Rare Disease Drug Rejection

2026-03-03 17:03:47

FDA refused approval for tabelecleucel in treating patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease earlier this year.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.